Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited in competition
WADA 2026: S6.A, non-specified, prohibited in competition. The future 2027 List retains this classification. Also designated a Substance of Abuse. [1] [2]
2026 and 2027 List, S6.A, printed pp.15–16; introductory definitions p.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Future 2027 wording
From 1 January 2027, the introduction also refers to metabolites when their presence is consistent with use of a Substance of Abuse. The designation alone does not determine a case outcome or sanction. [2]
Medicinal and other exposures
The reviewed US Goprelto label describes cocaine hydrochloride for local anesthesia during adult nasal procedures. USADA separately warns that coca leaves and coca tea can produce cocaine findings. Coca is not cocoa or cacao. [3] [4] [5]
- The epinephrine local-administration exception does not extend to cocaine.
Health concerns
Cocaine can cause severe cardiovascular or neurological harm, including heart attack and stroke. A medically used nasal formulation and nonmedical products are different exposures, and neither name alone authenticates a product’s contents. [6] [7]
- No individual risk estimate or safe-use claim is supported.
What remains uncertain
- Educational synthesis only; not individualized medical advice, a TUE decision or a sanction prediction.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Introduction p.3 · S6 pp.15–16
- WADA 2027 Prohibited List, 4 November revision ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected · FUTURE 2027 SOURCE
Introduction p.3 · S6 pp.15–16
- M12. FDA. Cocaine-hydrochloride products notification; Goprelto approval 14 December 2017. DailyMed product record. ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Goprelto indication; USADA coca-tea guidance
- M12. FDA. Cocaine-hydrochloride products notification; Goprelto approval 14 December 2017. DailyMed product record. ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Goprelto indication; USADA coca-tea guidance
- E6. USADA. Substances of Abuse 101, section Cocaine in Coca Tea. ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Goprelto indication; USADA coca-tea guidance
- H2. DEA. Cocaine; NIH MedlinePlus cocaine information. ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
DEA and MedlinePlus health effects
- H2. DEA. Cocaine; NIH MedlinePlus cocaine information. ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
DEA and MedlinePlus health effects
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.